Engineering allogeneic iPS cells to avoid transplant rejection

UCSF researchers have made headway toward developing universal allogeneic iPS cell therapies by identifying a dual mechanism that prevented immune rejection in mice.

Adult stem cells have shown limited efficacy as a regenerative

Read the full 324 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE